代谢手术术前内科管理进展

doi:10.3969/j.issn.1674-8115.2023.10.016

摘要/Abstract

摘要：

肥胖是一种慢性代谢性疾病，其人数日益增多，已成为包括中国在内的许多国家的重要公共卫生问题和流行病。肥胖及其合并症如2型糖尿病（type 2 diabetes mellitus，T2DM）、非酒精性脂肪肝、高血压和心血管疾病等严重危害生命健康。随着代谢手术的不断发展和完善，其作为一种安全、有效的治疗肥胖及其合并症的方法，已被广泛应用于肥胖患者的临床治疗中。代谢手术可以帮助患者显著减轻体质量，改善代谢指标，降低糖尿病、高血压等慢性病的风险，改善患者的生活质量，为患者带来全面的健康益处。然而，目前临床上缺乏规范的代谢手术术前内科管理，可能导致患者出现代谢紊乱、营养缺乏等并发症，从而增加手术风险和术后并发症发生率，影响减重的效果，对患者的预后造成不良影响。该文回顾了代谢手术术前减重、血糖控制、血压和血脂控制、微量营养素补充、心理和行为调节等方面的相关文献，对代谢手术术前内科管理进行综述，旨在为有效提高代谢手术的安全性和治疗效果，以及改善患者的预后提供参考。

关键词: 代谢手术, 肥胖, 糖尿病, 内科管理

Abstract:

Obesity is a chronic metabolic disease that is increasing in prevalence and has become a major public health problem and epidemic in many countries, including China. Obesity and its associated complications, such as type 2 diabetes (T2DM), non-alcoholic fatty liver disease, hypertension, and cardiovascular disease, seriously damage health. With the continuous development of metabolic surgery, it has become a widely used, safe and effective method for treating obesity and its associated complications. Metabolic surgery can significantly lose weight, improve metabolic indicators, reduce the risk of chronic diseases such as diabetes and hypertension, improve the quality of life of patients, and bring comprehensive health benefits to patients. However, there is currently a lack of standardized preoperative medical management for metabolic surgery, which may lead to metabolic disorders, nutrient deficiencies, and other complications, increasing the risk of surgery and postoperative complications, and affecting the efficacy of weight loss and the prognosis of patients. Through the systematic review of literature related to preoperative weight loss, glycemic control, blood pressure and lipid control, micronutrient supplementation, and psychological and behavioral modifications, this paper reviews preoperative medical management of metabolic surgery with the aim of providing reference for effectively improving the safety and efficacy of metabolic surgery and improving the prognosis of patients.

Key words: metabolic surgery, obesity, diabetes, medical management

中图分类号:

R589.2

单颖仪, 于浩泳. 代谢手术术前内科管理进展[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1332-1338.

SHAN Yingyi, YU Haoyong. Advances in preoperative medical management of metabolic surgery[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1332-1338.

图/表 2

参考文献 55

1	World Health Organization. Obesity and overweight[EB/OL]. (2021-06-09) [2023-03-28]. https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight.
2	WANG L, ZHOU B, ZHAO Z, et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18[J]. Lancet, 2021, 398(10294): 53-63.
3	ADAMS T D, DAVIDSON L E, LITWIN S E, et al. Weight and metabolic outcomes 12 years after gastric bypass[J]. N Engl J Med, 2017, 377(12): 1143-1155.
4	SCHAUER P R, BHATT D L, KIRWAN J P, et al. Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes[J]. N Engl J Med, 2017, 376(7): 641-651.
5	MINGRONE G, PANUNZI S, DE GAETANO A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial[J]. Lancet, 2021, 397(10271): 293-304.
6	SYN N L, CUMMINGS D E, WANG L Z, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants[J]. Lancet, 2021, 397(10287): 1830-1841.
7	ANGRISANI L, SANTONICOLA A, IOVINO P, et al. Bariatric surgery survey 2018: similarities and disparities among the 5 IFSO chapters[J]. Obes Surg, 2021, 31(5): 1937-1948.
8	DU X, DAI R, ZHOU H X, et al. Bariatric surgery in China: how is this new concept going?[J]. Obes Surg, 2016, 26(12): 2906-2912.
9	EISENBERG D, SHIKORA S A, AARTS E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery[J]. Surg Obes Relat Dis, 2022, 18(12): 1345-1356.
10	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4): 311-398.
	Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) [J]. Chinese Journal of Endocrinology and Metabolism, 2021, 37(4): 311-398.
11	VAN WISSEN J, BAKKER N, DOODEMAN H J, et al. Preoperative methods to reduce liver volume in bariatric surgery: a systematic review[J]. Obes Surg, 2016, 26(2): 251-256.
12	KOUTOUKIDIS D A, KOSHIARIS C, HENRY J A, et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Metabolism, 2021, 115: 154455.
13	ROMAN M, MONAGHAN A, SERRAINO G F, et al. Meta-analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes[J]. Br J Surg, 2019, 106(3): 181-189.
14	SAMAAN J S, ZHAO J, QIAN E, et al. Preoperative weight loss as a predictor of bariatric surgery postoperative weight loss and complications[J]. J Gastrointest Surg, 2022, 26(1): 86-93.
15	ANDERIN C, GUSTAFSSON U O, HEIJBEL N, et al. Weight loss before bariatric surgery and postoperative complications: data from the Scandinavian Obesity Registry (SOReg)[J]. Ann Surg, 2015, 261(5): 909-913.
16	SARNO G, CALABRESE P, FRIAS-TORAL E, et al. The relationship between preoperative weight loss and intra and post-bariatric surgery complications: an appraisal of the current preoperative nutritional strategies[J]. Crit Rev Food Sci Nutr, 2022: 1-9.
17	HUTCHEON D A, HALE A L, EWING J A, et al. Short-term preoperative weight loss and postoperative outcomes in bariatric surgery[J]. J Am Coll Surg, 2018, 226(4): 514-524.
18	TABESH M R, MALEKLOU F, EJTEHADI F, et al. Nutrition, physical activity, and prescription of supplements in pre- and post-bariatric surgery patients: a practical guideline[J]. Obes Surg, 2019, 29(10): 3385-3400.
19	WOLF R M, OSHIMA K, CANNER J K, et al. Impact of a preoperative low-calorie diet on liver histology in patients with fatty liver disease undergoing bariatric surgery[J]. Surg Obes Relat Dis, 2019, 15(10): 1766-1772.
20	LEAN M E J. Low-calorie diets in the management of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2019, 15(5): 251-252.
21	STEVEN S, HOLLINGSWORTH K G, AL-MRABEH A, et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders[J]. Diabetes Care, 2016, 39(5): 808-815.
22	PARRETTI H M, JEBB S A, JOHNS D J, et al. Clinical effectiveness of very-low-energy diets in the management of weight loss: a systematic review and meta-analysis of randomized controlled trials[J]. Obes Rev, 2016, 17(3): 225-234.
23	GASTALDO I, CASAS R, MOIZÉ V. Clinical impact of Mediterranean diet adherence before and after bariatric surgery: a narrative review[J]. Nutrients, 2022, 14(2): 393.
24	TETTAMANZI F, BAGNARDI V, LOUCA P, et al. A high protein diet is more effective in improving insulin resistance and glycemic variability compared to a Mediterranean diet: a cross-over controlled inpatient dietary study[J]. Nutrients, 2021, 13(12): 4380.
25	VICENTE MARTIN C, RABAGO TORRE L R, CASTILLO HERRERA L A, et al. Preoperative intragastric balloon in morbid obesity is unable to decrease early postoperative morbidity of bariatric surgery (sleeve gastrectomy and gastric bypass): a clinical assay[J]. Surg Endosc, 2020, 34(6): 2519-2531.
26	SARI C, SEIP R L, UMASHANKER D. Case report: off label utilization of topiramate and metformin in patients with BMI ≥50 kg/m² prior to bariatric surgery[J]. Front Endocrinol (Lausanne), 2021, 12: 588016.
27	GADDE K M, MARTIN C K, BERTHOUD H R, et al. Obesity: pathophysiology and management[J]. J Am Coll Cardiol, 2018, 71(1): 69-84.
28	AMINIAN A, BRETHAUER S A, ANDALIB A, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity[J]. Ann Surg, 2017, 266(4): 650-657.
29	JONES C E, GRAHAM L A, MORRIS M S, et al. Association between preoperative hemoglobin A1c levels, postoperative hyperglycemia, and readmissions following gastrointestinal surgery[J]. JAMA Surg, 2017, 152(11): 1031-1038.
30	HART A, GOFFREDO P, CARROLL R, et al. Optimizing bariatric surgery outcomes: the impact of preoperative elevated hemoglobin A1c levels on composite perioperative outcome measures[J]. Surg Endosc, 2021, 35(8): 4618-4623.
31	American Diabetes Association Professional Practice Committee. 16. diabetes care in the hospital: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S244-S253.
32	SIMHA V, SHAH P. Perioperative glucose control in patients with diabetes undergoing elective surgery[J]. JAMA, 2019, 321(4): 399-400.
33	MOREY-VARGAS O L, AMINIAN A, STECKNER K, et al. Perioperative management of diabetes in patients undergoing bariatric and metabolic surgery: a narrative review and the Cleveland Clinic practical recommendations[J]. Surg Obes Relat Dis, 2022, 18(8): 1087-1101.
34	MULLA C M, BALOCH H M, HAFIDA S. Management of diabetes in patients undergoing bariatric surgery[J]. Curr Diab Rep, 2019, 19(11): 112.
35	COURCOULAS A P, KING W C, BELLE S H, et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study[J]. JAMA Surg, 2018, 153(5): 427-434.
36	HAYOZ C, HERMANN T, RAPTIS D A, et al. Comparison of metabolic outcomes in patients undergoing laparoscopic roux-en-Y gastric bypass versus sleeve gastrectomy: a systematic review and meta-analysis of randomised controlled trials[J]. Swiss Med Wkly, 2018, 148: w14633.
37	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3): 221-255.
	Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guidelines for lipid management (2023)[J]. Chinese Journal of Cardiology, 2023, 51(3): 221-255.
38	GUAN B S, YANG J G, CHEN Y Y, et al. Nutritional deficiencies in Chinese patients undergoing gastric bypass and sleeve gastrectomy: prevalence and predictors[J]. Obes Surg, 2018, 28(9): 2727-2736.
39	AL-MUTAWA A, ANDERSON A K, ALSABAH S, et al. Nutritional status of bariatric surgery candidates[J]. Nutrients, 2018, 10(1): 67.
40	BEN-PORAT T, ELAZARY R, YUVAL J B, et al. Nutritional deficiencies after sleeve gastrectomy: can they be predicted preoperatively?[J]. Surg Obes Relat Dis, 2015, 11(5): 1029-1036.
41	ENANI G, BILGIC E, LEBEDEVA E, et al. The incidence of iron deficiency anemia post-Roux-en-Y gastric bypass and sleeve gastrectomy: a systematic review[J]. Surg Endosc, 2020, 34(7): 3002-3010.
42	PARROTT J M, CRAGGS-DINO L, FARIA S L, et al. The optimal nutritional programme for bariatric and metabolic surgery[J]. Curr Obes Rep, 2020, 9(3): 326-338.
43	SHERF DAGAN S, GOLDENSHLUGER A, GLOBUS I, et al. Nutritional recommendations for adult bariatric surgery patients: clinical practice[J]. Adv Nutr, 2017, 8(2): 382-394.
44	PARROTT J, FRANK L, RABENA R, et al. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the surgical weight loss patient 2016 update: micronutrients[J]. Surg Obes Relat Dis, 2017, 13(5): 727-741.
45	MOHAN S, SAMAAN J S, SAMAKAR K. Impact of smoking on weight loss outcomes after bariatric surgery: a literature review[J]. Surg Endosc, 2021, 35(11): 5936-5952.
46	INADOMI M, IYENGAR R, FISCHER I, et al. Effect of patient-reported smoking status on short-term bariatric surgery outcomes[J]. Surg Endosc, 2018, 32(2): 720-726.
47	WOOD G C, BENOTTI P N, LEE C J, et al. Evaluation of the association between preoperative clinical factors and long-term weight loss after Roux-en-Y gastric bypass[J]. JAMA Surg, 2016, 151(11): 1056-1062.
48	MALIK S, MITCHELL J E, ENGEL S, et al. Psychopathology in bariatric surgery candidates: a review of studies using structured diagnostic interviews[J]. Compr Psychiatry, 2014, 55(2): 248-259.
49	MÜLLER M, NETT P C, BORBÉLY Y M, et al. Mental illness has a negative impact on weight loss in bariatric patients: a 4-year follow-up[J]. J Gastrointest Surg, 2019, 23(2): 232-238.
50	CHAO A M, WADDEN T A, FAULCONBRIDGE L F, et al. Binge-eating disorder and the outcome of bariatric surgery in a prospective, observational study: two-year results[J]. Obesity (Silver Spring), 2016, 24(11): 2327-2333.
51	PEKKARINEN T, MUSTONEN H, SANE T M, et al. Long-term effect of gastric bypass and sleeve gastrectomy on severe obesity: do preoperative weight loss and binge eating behavior predict the outcome of bariatric surgery?[J]. Obes Surg, 2016, 26(9): 2161-2167.
52	FUCHS H F, LAUGHTER V, HARNSBERGER C R, et al. Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success[J]. Surg Endosc, 2016, 30(1): 251-258.
53	MECHANICK J I, APOVIAN C, BRETHAUER S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures—2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists[J]. Obesity (Silver Spring), 2020, 28(4): O1-O58.
54	CARTER J, CHANG J, BIRRIEL T J, et al. ASMBS position statement on preoperative patient optimization before metabolic and bariatric surgery[J]. Surg Obes Relat Dis, 2021, 17(12): 1956-1976.
55	MAREK R J, HEINBERG L J, LAVERY M, et al. A review of psychological assessment instruments for use in bariatric surgery evaluations[J]. Psychol Assess, 2016, 28(9): 1142-1157.

Treatment	Preoperative treatment	Note
Metformin	To discontinue on the day of surgery	Gastrointestinal discomfort and lactic acidosis should be avoided; Patients with stage 4 severe chronic kidney disease (CKD) [estimated glomerular filtration rate 30 mL·min^-1·(1.73 m²)^-1] are contraindicated
Sulfonylureas and meglitinides	To discontinue at the start of preoperative diet (i.e., 2‒4 weeks before surgery)	Hypoglycemia and weight gain should be avoided
Thiazolidinediones	To discontinue on the day of surgery	Weight gain, fluid retention, and edema should all be avoided
ɑ-glucosidase inhibitors	To discontinue on the day before metabolic surgery	Gastrointestinal side effects should be avoided
Dipeptidyl peptidase-4 (DPP-4) inhibitors	To discontinue on the day of surgery	Patients with heart failure, arthralgia, skin conditions, allergic reactions and acute pancreatitis should use it with caution
Sodium-glucose cotransporter-2 (SGLT2) inhibitors	To discontinue 3 d prior to surgery (2 weeks prior to surgery for those on a low-calorie ketogenic diet)	Genitourinary tract infections, hypotension, fractures, acute kidney injury, ketoacidosis, and rare cases of Fournier's gangrene should all be taken seriously
Glucagon-like peptide 1 (GLP-1) receptor agonists	To discontinue on the day of surgery	Gastrointestinal side effects should be avoided; Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are contraindicated

Treatment	Preoperative treatment	Note
Metformin	To discontinue on the day of surgery	Gastrointestinal discomfort and lactic acidosis should be avoided; Patients with stage 4 severe chronic kidney disease (CKD) [estimated glomerular filtration rate 30 mL·min^-1·(1.73 m²)^-1] are contraindicated
Sulfonylureas and meglitinides	To discontinue at the start of preoperative diet (i.e., 2‒4 weeks before surgery)	Hypoglycemia and weight gain should be avoided
Thiazolidinediones	To discontinue on the day of surgery	Weight gain, fluid retention, and edema should all be avoided
ɑ-glucosidase inhibitors	To discontinue on the day before metabolic surgery	Gastrointestinal side effects should be avoided
Dipeptidyl peptidase-4 (DPP-4) inhibitors	To discontinue on the day of surgery	Patients with heart failure, arthralgia, skin conditions, allergic reactions and acute pancreatitis should use it with caution
Sodium-glucose cotransporter-2 (SGLT2) inhibitors	To discontinue 3 d prior to surgery (2 weeks prior to surgery for those on a low-calorie ketogenic diet)	Genitourinary tract infections, hypotension, fractures, acute kidney injury, ketoacidosis, and rare cases of Fournier's gangrene should all be taken seriously
Glucagon-like peptide 1 (GLP-1) receptor agonists	To discontinue on the day of surgery	Gastrointestinal side effects should be avoided; Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are contraindicated

Micronutrient	Prevention	Treatment
Iron	45‒60 mg/d by oral administration	150‒200 mg/d by oral administration
Zinc	15 mg/d by oral administration	60 mg twice a day by oral administration
Copper	2 mg/d by oral administration (≥1 mg Cu per 8‒15 mg Zn to prevent copper deficiency is recommended)	Severe deficiency: 2‒4 mg/d by intravenous injection for 6 d
Vitamin A	6 000 IU/d by oral administration	Without corneal changes: 10 000‒25 000 IU/d by oral administration. With corneal changes: 50 000‒100 000 IU by intramuscular injection for 3 d, followed by 50 000 IU/d by intramuscular injection for 2 weeks to achieve clinical improvement
Vitamin B₁	12 mg/d by oral administration	500 mg/d by intravenous injection for 3‒5 d, followed by 250 mg/d by intravenous injection for 3‒5 d or until symptoms disappear. If further treatment is required, 100 mg/d is taken by oral administration
Vitamin B₆	400 μg/d by oral administration	1 000 μg/d by oral administration
Vitamin B₁₂	250‒350 μg/d or 1 000 μg/wk by sublingual administration	1 000‒2 000 μg/d by sublingual administration
Vitamin D₂or D₃	Vitamin D₂ or D₃ 3 000 IU/d by oral administration to reach normal concentrations of 30 ng/mL	Vitamin D₂ or D₃ 50 000 IU/week for 8 weeks, followed by maintenance therapy of 1 500‒2 000 IU/d by oral administration to achieve normal concentrations
Vitamin E	400 IU/d by oral administration	800‒1 200 IU/d by oral administration
Vitamin K	300 μg/d by oral administration	10 mg by intramuscular injection, followed by 1‒2 mg/week by oral administration

Micronutrient	Prevention	Treatment
Iron	45‒60 mg/d by oral administration	150‒200 mg/d by oral administration
Zinc	15 mg/d by oral administration	60 mg twice a day by oral administration
Copper	2 mg/d by oral administration (≥1 mg Cu per 8‒15 mg Zn to prevent copper deficiency is recommended)	Severe deficiency: 2‒4 mg/d by intravenous injection for 6 d
Vitamin A	6 000 IU/d by oral administration	Without corneal changes: 10 000‒25 000 IU/d by oral administration. With corneal changes: 50 000‒100 000 IU by intramuscular injection for 3 d, followed by 50 000 IU/d by intramuscular injection for 2 weeks to achieve clinical improvement
Vitamin B₁	12 mg/d by oral administration	500 mg/d by intravenous injection for 3‒5 d, followed by 250 mg/d by intravenous injection for 3‒5 d or until symptoms disappear. If further treatment is required, 100 mg/d is taken by oral administration
Vitamin B₆	400 μg/d by oral administration	1 000 μg/d by oral administration
Vitamin B₁₂	250‒350 μg/d or 1 000 μg/wk by sublingual administration	1 000‒2 000 μg/d by sublingual administration
Vitamin D₂or D₃	Vitamin D₂ or D₃ 3 000 IU/d by oral administration to reach normal concentrations of 30 ng/mL	Vitamin D₂ or D₃ 50 000 IU/week for 8 weeks, followed by maintenance therapy of 1 500‒2 000 IU/d by oral administration to achieve normal concentrations
Vitamin E	400 IU/d by oral administration	800‒1 200 IU/d by oral administration
Vitamin K	300 μg/d by oral administration	10 mg by intramuscular injection, followed by 1‒2 mg/week by oral administration

[1]	贾君杰, 邢海帆, 张群子, 刘奇烨, 汪年松, 范瑛. 缺氧诱导因子-1α抑制剂YC-1改善糖尿病肾病小鼠肾脏损伤的机制研究[J]. 上海交通大学学报（医学版）, 2023, 43(9): 1089-1098.
[2]	吴凯敏, 麻静, 赵旭赟. 间歇性禁食联合产热脂肪活化防治小鼠肥胖作用研究[J]. 上海交通大学学报（医学版）, 2023, 43(9): 1131-1144.
[3]	薛彦斌, 齐季瑛, 张子政, 经仁洁, 孙文, 姚华彦, 何萍, 崔斌, 宁光. 上海糖尿病临床专病大数据库建设与真实世界研究[J]. 上海交通大学学报（医学版）, 2023, 43(9): 1145-1152.
[4]	卢晓冰, 岳江, 何晟赟, 董莹, 路青, 麻静. 大腿骨骼肌肌内脂肪组织的含量对肥胖症男性患者糖代谢的影响[J]. 上海交通大学学报（医学版）, 2023, 43(9): 1169-1174.
[5]	吴凌恒, 陈建雄, 张梦娇, 沙蕾, 曹萌萌, 沈崔琴, 杜联芳, 李朝军. 血糖控制不理想对2型糖尿病患者亚临床心肌收缩功能的影响研究[J]. 上海交通大学学报（医学版）, 2023, 43(8): 1024-1031.
[6]	高楠, 郝璨, 马冰洁, 靳天, 马柯, 刘晓明. 转位分子蛋白经由Keap1/Nrf2/HO-1通路激活自噬缓解大鼠糖尿病神经病理性疼痛[J]. 上海交通大学学报（医学版）, 2023, 43(8): 988-996.
[7]	王景慧, 张红, 张蓉, 彭丹凤, 余海蓉, 陈香慧, 宣晔, 胡承, 顾云娟. 利用全外显子测序在肥胖人群中筛查致病突变[J]. 上海交通大学学报（医学版）, 2023, 43(7): 882-889.
[8]	孟祥雨, 闫丹丹, 陈香慧, 赖思宇, 徐云, 耿瑞娜, 张红, 张蓉, 胡承, 严婧. 家系全外显子组测序鉴定Wolfram综合征致病突变及其临床性状分析[J]. 上海交通大学学报（医学版）, 2023, 43(7): 898-905.
[9]	刘芊若, 方子晨, 吴宇涵, 钟羡欣, 国沐禾, 贾洁. 肠道菌群及其代谢产物与妊娠期糖尿病相关性的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 641-647.
[10]	张越, 瞿蕾, 谷沁, 朱亦清, 马莉莹, 孙文广. 妊娠期糖尿病孕妇尿酮体持续阳性对母婴临床结局的影响[J]. 上海交通大学学报（医学版）, 2023, 43(3): 314-319.
[11]	陈奕馨, 程丽珍, 林祎嘉, 苗雅. 2型糖尿病脑病小鼠海马中转录因子EB活性与自噬功能的变化[J]. 上海交通大学学报（医学版）, 2023, 43(2): 162-170.
[12]	张娟, 葛晓旭, 张荣, 蒋伏松, 蒋燕燕, 李鸣, 李甜甜, 刘婵薇, 陈亚婷, 刘丽梅. 青少年的成人起病型糖尿病家系NEUROD1基因突变的筛查与功能解析[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1255-1261.
[13]	吴瑞芳, 冯明, 孟健. 脂肪酸结合蛋白4在肥胖相关肿瘤中的作用综述[J]. 上海交通大学学报（医学版）, 2023, 43(10): 1311-1316.
[14]	吴佳晋, 钟晨, 李大伟, 陈若洋, 瞿俊文, 张明. 甲基转移酶3调控pri-miR-21甲基化修饰在糖尿病肾病肾脏纤维化中的作用[J]. 上海交通大学学报（医学版）, 2023, 43(1): 1-7.
[15]	谢小雷, 江佩欣, 张敬鸿, 莫骏健, 吴可凡, 曾康逸. 视网膜母细胞瘤结合锌指蛋白1调控肥胖和肿瘤信号通路研究综述[J]. 上海交通大学学报（医学版）, 2023, 43(1): 114-119.